Profund Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Profund Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Sell	309,097 -87,292	-22%	-$291K	0.03%	316
2026 Q1	$1.22M	Buy	396,389 +39,727	+11%	+$154K	0.04%	297
2025 Q4	$1.46M	Buy	356,662 +195,207	+121%	+$967K	0.04%	270
2025 Q3	$788K	Buy	161,455 +84,429	+110%	+$443K	0.03%	381
2025 Q2	$390K	Sell	77,026 -46,098	-37%	-$226K	0.01%	554
2025 Q1	$651K	Buy	123,124 +8,238	+7%	+$60.1K	0.03%	402
2024 Q4	$777K	Sell	114,886 -17,925	-13%	-$121K	0.03%	351
2024 Q3	$875K	Buy	132,811 +58,040	+78%	+$416K	0.03%	357
2024 Q2	$561K	Sell	74,771 -52,385	-41%	-$457K	0.02%	467
2024 Q1	$1.27M	Sell	127,156 -35,469	-22%	-$395K	0.05%	298
2023 Q4	$1.6M	Sell	162,625 -21,610	-12%	-$154K	0.07%	225
2023 Q3	$1.41M	Buy	184,235 +124,621	+209%	+$1.24M	0.08%	206
2023 Q2	$445K	Sell	59,614 -11,610	-16%	-$81.2K	0.02%	548
2023 Q1	$475K	Buy	+71,224	New	+$565K	0.03%	516

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Profund Advisors's RXRX Position: Q2 2026 in Review

Profund Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 22% in Q2 2026, selling an estimated $291K and leaving 309,097 shares worth $1.13M. The position accounts for 0.03% of the portfolio, ranked #316.

Profund Advisors first reported a position in RXRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.6M in Q4 2023. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Profund Advisors held 309,097 shares of Recursion Pharmaceuticals worth $1.13M as of Q2 2026.
Profund Advisors sold 87,292 Recursion Pharmaceuticals shares in Q2 2026, an estimated $291K.
Recursion Pharmaceuticals made up 0.03% of Profund Advisors's portfolio in Q2 2026, its #316 holding.
Profund Advisors first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Profund Advisors's Recursion Pharmaceuticals position peaked at $1.6M in Q4 2023.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.